Can I Take Melatonin With Evenity (Romosozumab)?

Import from '@/components/mdx'

What Is the Interaction Risk Between Melatonin and Romosozumab?

The short answer: the combination is unlikely to cause a clinically meaningful drug interaction for most postmenopausal women. Romosozumab is a monoclonal antibody that does not travel through cytochrome P450 liver pathways, so supplements that do affect CYP enzymes are unlikely to change its blood levels. Melatonin is not a significant CYP inducer at typical sleep doses. The concern that does exist is pharmacodynamic, not pharmacokinetic, and centers on melatonin's effects on insulin sensitivity and glucose regulation.

How Romosozumab Works in the Body

Romosozumab binds and inhibits sclerostin, a protein produced by osteocytes that normally suppresses bone formation. By blocking sclerostin, romosozumab simultaneously increases bone formation and decreases bone resorption, a dual effect not seen with other osteoporosis drugs. In the FRAME trial, one year of romosozumab reduced new vertebral fractures by 73% compared with placebo in postmenopausal women with osteoporosis. Because it is a large-molecule biologic given as a subcutaneous injection, romosozumab is broken down through protein catabolism, the same route as other endogenous proteins, rather than through hepatic phase I or phase II metabolism.

How Melatonin Is Processed

Melatonin is primarily metabolized in the liver via CYP1A2, with a half-life of roughly 40 to 60 minutes for immediate-release formulations. At standard sleep doses of 0.5 mg to 5 mg, melatonin does not meaningfully induce or inhibit the enzymes relevant to romosozumab's clearance, because romosozumab has no hepatic clearance pathway to disrupt.

The Pharmacodynamic Concern: Glucose and Insulin Sensitivity

Melatonin receptors (MT1 and MT2) are expressed in pancreatic beta cells. Higher melatonin levels are associated with reduced insulin secretion in some studies. A 2022 Mendelian randomization analysis published in Diabetes Care found that genetically predicted higher melatonin signaling was associated with higher fasting glucose and lower insulin secretion. This is not a catastrophic drug interaction, but it is a clinically relevant signal if you already have impaired fasting glucose, type 2 diabetes, or PCOS-related insulin resistance alongside your osteoporosis.

Romosozumab itself has a modest adverse cardiovascular signal identified in the ARCH trial, where the romosozumab group had slightly more serious cardiovascular events in the first year compared with alendronate. Women with pre-existing metabolic syndrome should discuss both the cardiovascular label warning and melatonin's glucose effects with their prescriber before starting either agent.

Who Takes Romosozumab, and Why Sleep Comes Up

Romosozumab is approved by the FDA for postmenopausal women with osteoporosis at high or very high risk of fracture. The treatment window is exactly 12 monthly injections. After that, you transition to an antiresorptive agent such as a bisphosphonate or denosumab to hold the bone gains.

Sleep in the Postmenopausal Years

Sleep disruption is one of the most common complaints during perimenopause and postmenopause. Vasomotor symptoms, changing progesterone levels, and circadian rhythm shifts all contribute. A 2023 analysis in Menopause reviewed the bidirectional relationship between poor sleep and bone loss, noting that short sleep duration is independently associated with lower bone mineral density in postmenopausal women. This is the clinical reality: many women on Evenity are also reaching for melatonin to manage exactly the sleep problems that may be contributing to their bone fragility in the first place.

Why Women Ask About This Combination Specifically

Women on Evenity are typically in their late 50s to 70s, a group that has also seen a steep rise in melatonin use. According to data published in JAMA, melatonin use among U.S. Adults increased fivefold between 1999 and 2018, with older adults being among the fastest-growing user groups. The question is not surprising. It is a reasonable, specific thing to want answered before mixing the two.

Melatonin and Bone Health: Is There Any Benefit?

Here is a framework that does not appear in the standard interaction databases: melatonin may not just be a passive sleep aid in the context of osteoporosis treatment. It appears to have direct effects on bone metabolism, and those effects are relevant when you are actively trying to build bone on Evenity.

Preclinical Evidence

Melatonin has been shown in preclinical models to stimulate osteoblast differentiation and inhibit osteoclast activity through antioxidant pathways and MT2 receptor signaling on bone cells. A review published in Frontiers in Endocrinology summarized animal studies showing that melatonin administration increased bone mineral density and trabecular thickness in rodent models of estrogen deficiency.

Human Data: Thin but Directional

Human trial data on melatonin for bone outcomes is sparse. A small randomized controlled trial by Amstrup et al. in 81 postmenopausal women found that nightly melatonin (1 mg or 3 mg) for one year was associated with improved femoral neck bone mineral density compared with placebo, along with reductions in bone turnover markers. This is a single small trial and should not be taken as definitive proof of benefit. The sample size was insufficient to draw strong conclusions, and the effect size was modest. Still, if you are already on Evenity for bone building, the preclinical and early clinical signals do not suggest that melatonin would work against your treatment goals.

What This Means Clinically

The evidence does not support adding melatonin specifically to augment romosozumab's effect. Use melatonin if you need it for sleep. The bone biology signals are hypothesis-generating, not practice-changing.

Sex-Specific Pharmacology: What Changes for Women

Romosozumab was studied almost exclusively in postmenopausal women, which is unusual for a drug class and actually gives us better sex-specific data than most. The FRAME trial enrolled 7,180 postmenopausal women with a mean age of 71 years. The ARCH trial enrolled 4,093 postmenopausal women comparing romosozumab followed by alendronate versus alendronate alone.

Estrogen Deficiency as the Core Driver

The bone loss that creates the need for romosozumab in most women is driven by estrogen withdrawal at menopause. Estrogen normally suppresses sclerostin production in osteocytes. When estrogen falls, sclerostin rises, bone formation slows, and resorption accelerates. Romosozumab directly counters this mechanism. Melatonin's endogenous levels also decline with age and are further disrupted by the circadian changes of menopause, which is one reason the overlap of insomnia and osteoporosis is so common in this population.

Body Composition and Dosing

Romosozumab is dosed at a flat 210 mg (two 105 mg injections) regardless of body weight. Melatonin clearance can be slower in older women due to reduced CYP1A2 activity with age, meaning a standard 5 mg tablet may produce higher plasma levels than expected. Starting with a lower dose (0.5 mg to 1 mg) is reasonable in women over 65.

Pregnancy, Lactation, and Contraception: Required Reading

Romosozumab is contraindicated in pregnancy. This is a firm contraindication, not a relative one.

Pregnancy Category and Human Data

Romosozumab has no FDA pregnancy category under the current labeling system, but the FDA prescribing information states that romosozumab may cause fetal harm based on animal studies. In pregnant rats and rabbits given romosozumab at doses equivalent to human exposure, skeletal abnormalities and fetal death were observed. There are no adequate and well-controlled studies in pregnant women, and the drug should not be used during pregnancy.

Who Needs to Think About This

Romosozumab is primarily used in postmenopausal women, so pregnancy is not typically a concern for the core prescribing population. The exception is premenopausal women with severe osteoporosis (for example, those with glucocorticoid-induced bone loss, anorexia-related bone disease, or rare primary osteoporosis), who are sometimes considered for anabolic bone therapy off-label. If you are a woman of reproductive age receiving romosozumab for any reason, you need effective contraception throughout the 12-month treatment course. Discuss contraceptive options with your prescriber before starting.

Lactation

There are no data on romosozumab transfer into human breast milk. Because it is a large-molecule IgG2 monoclonal antibody, transfer into milk is expected to be low, as is the case with most monoclonal antibodies. However, the absence of data means no safety statement can be made. Breastfeeding is not recommended during romosozumab treatment.

Melatonin in Pregnancy and Lactation

Melatonin crosses the placenta and transfers into breast milk. Human safety data in pregnancy are very limited. A small number of studies suggest it may have neuroprotective effects in preterm infants, but these are investigational contexts, not endorsements for routine use. The ACOG advises caution with melatonin in pregnancy given insufficient safety data. Avoid melatonin during pregnancy and discuss with your provider before using it while breastfeeding.

Who This Combination Is Right For (and Who Should Pause)

Likely Fine

• Postmenopausal women on Evenity using melatonin at 0.5 mg to 3 mg for sleep, with normal fasting glucose and no cardiovascular disease history.
• Women experiencing sleep disruption from vasomotor symptoms who need a short-term sleep aid during their 12-month Evenity course.
• Women whose sleep deprivation is actively impairing quality of life and who have tried non-pharmacological approaches first (sleep hygiene, CBT-I).

Worth Discussing With Your Prescriber First

• Women with type 2 diabetes, prediabetes, or PCOS-related insulin resistance, given melatonin's effects on insulin secretion.
• Women with a history of cardiovascular disease or stroke, given the ARCH trial cardiovascular signal with romosozumab.
• Women taking other medications that affect melatonin metabolism, including fluvoxamine (a strong CYP1A2 inhibitor that can increase melatonin levels dramatically) or rifampin (a strong CYP1A2 inducer that reduces melatonin levels).

Not Right For

• Pregnant women or women planning pregnancy during the 12-month romosozumab course.
• Women who are breastfeeding.
• Women who have already had a myocardial infarction or stroke within the past year, as romosozumab carries a black box warning for this population.

Practical Guidance: How to Take Both Safely

Timing

Romosozumab is a once-monthly subcutaneous injection given in your clinician's office. There is no specific time-of-day requirement that creates a conflict with a nightly melatonin dose. Take melatonin 30 to 60 minutes before your target bedtime.

Dose

Start with the lowest effective melatonin dose. For sleep onset, 0.5 mg is often as effective as higher doses in clinical studies, with less morning grogginess. The common 5 mg to 10 mg doses sold over the counter are pharmacological rather than physiological and are not well-validated in postmenopausal women for long-term use.

Monitoring

Your Evenity prescriber will order periodic bone density scans and bone turnover markers (typically serum P1NP and CTX) during and after treatment. If you also have metabolic risk factors, a fasting glucose check at the start of melatonin use is a simple precaution. No special monitoring protocol exists specifically for this combination.

Tell Your Care Team

Melatonin is available without a prescription and many women do not mention it at appointments. Your Evenity prescriber and your primary care clinician both need to know you are taking it, especially if your medication list includes fluvoxamine, hormonal therapies, or anticoagulants (melatonin has antiplatelet properties at higher doses based on in vitro data).

The Evidence Gap: What We Do Not Know

Women have been historically underrepresented in supplement-drug interaction research. The specific combination of melatonin and romosozumab has not been studied in a clinical trial. Everything in this article about their interaction is based on:

1. The known pharmacology of each agent separately.
2. Mechanistic inference from romosozumab's protein catabolism route.
3. Melatonin's CYP1A2-mediated clearance and MT receptor pharmacology.
4. Observational and Mendelian randomization data on melatonin and glucose.

This is honest, not a limitation to be embarrassed about. The absence of a documented interaction in the Natural Medicines database and the pharmacological logic that no CYP-mediated interaction can exist are both reassuring. What we cannot yet say with certainty is whether the combination produces any additive cardiovascular effect or whether melatonin's glucose effects are clinically meaningful in the specific population of postmenopausal women with osteoporosis and metabolic comorbidities. Studies in this exact population are needed.

A Note on Other Supplements Commonly Combined With Evenity

Calcium and vitamin D are foundational to any osteoporosis regimen and were co-administered with romosozumab in both the FRAME and ARCH trials. Per The Menopause Society's 2023 position statement, adequate calcium intake (1,200 mg daily from food and supplements combined) and vitamin D sufficiency (25-hydroxyvitamin D above 30 ng/mL) are recommended for all postmenopausal women receiving bone-active therapy.

Magnesium, collagen peptides, and vitamin K2 are frequently asked about in this population. None have a documented interaction with romosozumab. Magnesium is worth mentioning because it is also used for sleep and can be taken alongside melatonin; there is no evidence that the two supplements interact adversely with each other or with Evenity.